ArticleUrologic oncology2014
Essential elements of personalized medicine.
Article in Urologic oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Precision cancer medicine and the doctor-patient relationship: a systematic review and narrative synthesis.BMC medical informatics and decision making · 2023Pooled it
- Representations of personalised medicine in family medicine: a qualitative analysis.BMC primary care · 2022Article
- A case report of the sustained and rapid response of bevacizumab in a TP53-positive breast cancer and liver metastatic patient through personalized medicine.Frontiers in oncology · 2022Article
- The placebo phenomenon and the underlying mechanisms.Hormones (Athens, Greece) · 2021Review
- Redefining value: a discourse analysis on value-based health care.BMC health services research · 2020Article
- "I need to know what makes somebody tick …": Challenges and Strategies of Implementing Shared Decision-Making in Individualized Oncology.The oncologist · 2019Article
- Person Centered Care and Personalized Medicine: Irreconcilable Opposites or Potential Companions?Health care analysis : HCA : journal of health philosophy and policy · 2019Article
- Analysis of free text in electronic health records for identification of cancer patient trajectories.Scientific reports · 2017Article
- From "Personalized" to "Precision" Medicine: The Ethical and Social Implications of Rhetorical Reform in Genomic Medicine.The Hastings Center report · 2016Article
- Conceptual and terminological confusion around personalised medicine: a coping strategy.BMC medical ethics · 2016Article
- Toward precision medicine of breast cancer.Theoretical biology & medical modelling · 2016Review
- Genetics and the placebo effect: the placebome.Trends in molecular medicine · 2015Review
- "Getting off the Bus Closer to Your Destination": Patients' Views about Pharmacogenetic Testing.The Permanente journal · 2015Article
- Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs.BMC cancer · 2014Article
- Personalised medicine, disease prevention, and the inverse care law: more harm than benefit?European journal of epidemiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesGenomic information has been promoted as the basis for "personalized" health care. We considered the benefits provided by genomic testing in context of the concept of personalized medicine. MATERIALS AND
methodsWe evaluated current and potential uses of genomic testing in health care, using prostate cancer as an example, and considered their implications for individualizing or otherwise improving health care. RESULTS AND
conclusionsPersonalized medicine is most accurately seen as a comprehensive effort to tailor health care to the individual, spanning multiple dimensions. While genomic tests will offer many potential opportunities to improve the delivery of care, including the potential for genomic research to offer opportunities to improve prostate cancer screening and treatment, such advances do not in themselves constitute a paradigm shift in the delivery of health care. Rather, personalized medicine is based on a partnership between clinician and patient that utilizes shared decision making to determine the best health care options among the available choices, weighing the patient's personal values and preferences together with clinical findings. This approach is particularly important for difficult clinical decisions involving uncertainty and trade-offs, such as those involved in prostate cancer screening and management. The delivery of personalized medicine also requires adequate health care access and assurance that basic health needs have been met. Substantial research investment will be needed to identify how genomic tests can contribute to this effort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.